The professor from The University of Texas MD Anderson Cancer Center discussed long-term follow-up analysis of the phase 2 ZUMA-5 trial.
This content originally appeared on our sister site, OncLive.
OncLive spoke with Sattva S. Neelapu, MD, professor and deputy department chair, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, to learn more about the long-term follow-up analysis of the phase 2 ZUMA-5 trial (NCT03105336) of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Updated findings from the ZUMA-5 trial, with at least 2 years of follow-up, were presented at the American Society of Hematology 2021 Meeting, December 11-14. Altogether, 149 patients were treated on the study. Among the efficacy-evaluable population (n = 110), the complete response rate was 79% in patients with follicular lymphoma and 63% in patients with marginal zone lymphoma (MZL), Neelapu explains.
After a median follow-up of 30.9 months in the follicular lymphoma cohort, 57% of patients remain in ongoing response, and the estimated median PFS was about 39.6 months, Neelapu continues. In the MZL cohort, the median follow-up was 23.8 months and 50% of the patients remain in remission, Neelapu concludes.